A woman’s quality of life is affected by many symptoms of perimenopause. Postmenopause hormone therapy can help with these symptoms. There are health risks associated with the combination of equine estrogen and medroxyprogesterone. Some women think compounded bioidentical Hormone Therapy is a safer alternative. Some women think compounded bioidentical HT is a safer alternative. There are similarities and differences in the US Food and Drug Administration. The major claims will be looked into and it’s for the management of patients who request it from their doctor.
Quality of life can be affected by hormones associated with perimenopause and menopause. Symptoms can include poor concentration, hot flashes, and night sweats. Post-menopause hormones are one of the most effective ways to treat menopausal symptoms. Women want compounded bioidentical hormones from their doctors if they think it’s safer than FDA-approved therapy. Estradiol and progestogens can be used by women to treat menstruation. Many FDA-approved and non-FDA-approved Estrogens and Progestogens can be used to treat menopausal symptoms.
The term bioidentical hormone in therapy Utah doesn’t have a standard definition, making it confusing for patients and practitioners. There are different expectations for women when they ask for bioidentical hormones. It can mean any of the following: natural, compounded, plant-derived, or similar to the human hormone structure. The structure and function of bioidentical hormones are the same as hormones produced in the human body. This broad definition does not address the manufacturing, source, and delivery methods of the products. They are manufactured under strict standards and subjected to scientific scrutiny.
Several peer-reviewed publications document the benefits of various doses of FDA-approved estrogen products. There is no evidence that the FDA-approved products for the treatment of the symptoms of menopause offer clinically relevant benefits. It is possible to tailor therapy to meet the needs and expectations of patients who want relief from menopausal symptoms. Each patient should be aware of the risks and benefits of the therapy, and they should only prescribe products that they are familiar with.
Several FDA-approved hormones can be used to treat menopausal symptoms. Those who meet the definition of bioidentical and those who are not are included. There are natural, nonhuman conjugated estrogens in the products. There are either plant-derived bioidentical estrogens, progestogens, or a combination of the two. Derived from the urine of pregnant mares, synthetic conjugated estrogens and progestins are not bioidentical to human sex steroid hormones.
There are FDA-approved products that have bioidentical hormones. The effects of these preparations are subject to scientific scrutiny, and they are manufactured under strict standards. The beneficial effects of various doses of FDA-approved estrogen products have been documented in several peer-reviewed publications. There have not been large-scale, randomized, controlled studies conducted for custom CBHT.
There is no evidence that the FDA-approved products for the treatment of the symptoms of menopause offer clinically relevant benefits. FDA-approved HT products can be tailored to meet the needs and expectations of patients due to their wide array of formulas, dosages, and delivery systems. Women who can’t tolerate FDA-approved products or nonhormonal ingredients can be prescribed CBHT. The risks and benefits of the proposed therapy should be discussed with each patient and only the products that they are familiar with should be prescribed.
Observational studies and the WHI HT trial have established an association between HT (E+P) and an increased risk of breast cancer. The decreased activity of estradiol is associated with a reduced breast cancer risk. There are no controlled trials to back up the claims that it protects against cancer. There are concerns about the risks of stimulating breast parenchyma and the continued use of estriol in high doses. The added progestin may have increased the risk of breast cancer in the E+P arm of the WHI.
Many clinicians use prometrium as their preferred formula. (Abbott Laboratories, Abbott Park, IL), The FDA-approved form of oral progesterone is the same as the original form and has better bioavailability. A combination of hormones decreased the risk of histology and breast cancer in an observational study. More study is needed to establish long-term safety. There are few published studies about the safety and effectiveness of CBHT. Clinical trials are necessary to provide evidence of long-term safety for patients, and they need to be aware of the risks and benefits.
BHT Has A Better Effect On Bones Than The FDA-Approved Version Of It.
Among the claims in favor of CBHT for better bone health are the scientifically based observations about the benefits of estrogen and testosterone in preventing bone loss, as well as the suggestion of progesterone as an agent that could help rebuild lost bone. Many peer-reviewed studies show a beneficial effect of manufactured estrogen and testosterone in preventing postmenopausal bone loss. There is only one study that shows a reduction in hip fracture risk with E+P therapy. The claims haven’t been substantiated or correlated with the wide variety of CBHT preparations used. The claims of preventing bone loss and rebuilding lost bones have not been proven.